Wuhan YZY Biopharma Co., Ltd. (HKG:2496)

Hong Kong · Delayed Price · Currency is HKD

4.300

-0.860 (-16.67%)

May 28, 2026, 3:13 PM HKT

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Discovering, Developing and Commercializing New Class of Innovative Medicines	66.86M	107.81M	-	-	-
Discovering, Developing and Commercializing New Class of Innovative Medicines Growth	-37.99%	-	-	-	-
Pharmaceuticals	-	-	-	2.28M	12.16M
Pharmaceuticals Growth	-	-	-	-81.28%	-
Total	66.86M	107.81M	-	2.28M	12.16M
Total Growth	-37.99%	-	-	-81.28%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
People's Republic of China	66.86M	107.81M	-	2.28M	12.16M
People's Republic of China Growth	-37.99%	-	-	-81.28%	-
Total	66.86M	107.81M	-	2.28M	12.16M
Total Growth	-37.99%	-	-	-81.28%	-

Source: S&P Global Market Intelligence.